John Mullinax

7PUBLICATIONS
44CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Nov 30, 2025
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee.

George Coukos, Marco Donia, Brian R Gastman

|Jan 21, 2025
Art of TIL immunotherapy: SITC's perspective on demystifying a complex treatment.

Simon Turcotte, Marco Donia, Brian Gastman

|Jul 27, 2024
Oncolytic Viral Therapy in Osteosarcoma.

Thomas Karadimas, Thien Huong Huynh, Chloe Chose

|Oct 06, 2023
Neoantigen-specific CD4<sup>+</sup> tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients.

MacLean S Hall, Jamie K Teer, Xiaoqing Yu

|Oct 10, 2022
Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.

MacLean S Hall, John E Mullinax, Cheryl A Cox

|Jan 29, 2021
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma.

Michael D Jain, Hua Zhao, Xuefeng Wang

Pageof 2

Frequent Collaborators

2 joint publications

Michael Jain

2 joint publications

Xuefeng Wang

2 joint publications

Christina Bachmeier

2 joint publications

Aleksandr Lazaryan